Progress and challenges in melanoma immunotherapy
Melanoma is highly invasive and has a high mortality rate. The effectiveness of traditional treatment methods is limited. Immunotherapy based on immune checkpoint inhibitors has achieved a major breakthrough in melanoma treatment. Among them, classic immune checkpoint inhibitors, such as CTLA-4, PD-...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
editoiral office of Journal of Diagnosis and Therapy on Dermato-venereology
2025-07-01
|
| Series: | Pifu-xingbing zhenliaoxue zazhi |
| Subjects: | |
| Online Access: | http://pfxbzlx.gdvdc.com/EN/10.3969/j.issn.1674-8468.2025.07.005 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849236800529235968 |
|---|---|
| author | LIN Jing CHEN Yaying CHEN Yu |
| author_facet | LIN Jing CHEN Yaying CHEN Yu |
| author_sort | LIN Jing |
| collection | DOAJ |
| description | Melanoma is highly invasive and has a high mortality rate. The effectiveness of traditional treatment methods is limited. Immunotherapy based on immune checkpoint inhibitors has achieved a major breakthrough in melanoma treatment. Among them, classic immune checkpoint inhibitors, such as CTLA-4, PD-1/PD-L1, have a landmark significance in the field of immuno-oncology. Meanwhile, emerging checkpoint inhibitors, including LAG-3, TIM-3, and TIGIT, have demonstrated promising new therapeutic effects. Significant progress has also been made in cellular therapies and neoantigen-based vaccines. Currently, immunotherapy combination regimens significantly enhance the therapeutic effect through the synergistic action of multiple mechanisms, but they also face challenges such as immune-related adverse reactions and immune resistance. Future research directions lie in exploring novel combined targets, integrating cutting-edge technologies, developing personalized treatment plans, and implementing strategies such as resistance monitoring, to overcome current therapeutic limitations. This article systematically summarizes the latest progress and existing challenges in the immunotherapy of melanoma, aiming to provide new insights and references for clinical practice and scientific research. |
| format | Article |
| id | doaj-art-06fd142f83d848439a94690da69c91a7 |
| institution | Kabale University |
| issn | 1674-8468 |
| language | zho |
| publishDate | 2025-07-01 |
| publisher | editoiral office of Journal of Diagnosis and Therapy on Dermato-venereology |
| record_format | Article |
| series | Pifu-xingbing zhenliaoxue zazhi |
| spelling | doaj-art-06fd142f83d848439a94690da69c91a72025-08-20T04:02:09Zzhoeditoiral office of Journal of Diagnosis and Therapy on Dermato-venereologyPifu-xingbing zhenliaoxue zazhi1674-84682025-07-0132749250110.3969/j.issn.1674-8468.2025.07.005Progress and challenges in melanoma immunotherapyLIN Jing0CHEN Yaying1CHEN Yu2Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, ChinaClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, ChinaClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, ChinaMelanoma is highly invasive and has a high mortality rate. The effectiveness of traditional treatment methods is limited. Immunotherapy based on immune checkpoint inhibitors has achieved a major breakthrough in melanoma treatment. Among them, classic immune checkpoint inhibitors, such as CTLA-4, PD-1/PD-L1, have a landmark significance in the field of immuno-oncology. Meanwhile, emerging checkpoint inhibitors, including LAG-3, TIM-3, and TIGIT, have demonstrated promising new therapeutic effects. Significant progress has also been made in cellular therapies and neoantigen-based vaccines. Currently, immunotherapy combination regimens significantly enhance the therapeutic effect through the synergistic action of multiple mechanisms, but they also face challenges such as immune-related adverse reactions and immune resistance. Future research directions lie in exploring novel combined targets, integrating cutting-edge technologies, developing personalized treatment plans, and implementing strategies such as resistance monitoring, to overcome current therapeutic limitations. This article systematically summarizes the latest progress and existing challenges in the immunotherapy of melanoma, aiming to provide new insights and references for clinical practice and scientific research.http://pfxbzlx.gdvdc.com/EN/10.3969/j.issn.1674-8468.2025.07.005melanomaimmunotherapycell therapytumor vaccineimmunoresistance |
| spellingShingle | LIN Jing CHEN Yaying CHEN Yu Progress and challenges in melanoma immunotherapy Pifu-xingbing zhenliaoxue zazhi melanoma immunotherapy cell therapy tumor vaccine immunoresistance |
| title | Progress and challenges in melanoma immunotherapy |
| title_full | Progress and challenges in melanoma immunotherapy |
| title_fullStr | Progress and challenges in melanoma immunotherapy |
| title_full_unstemmed | Progress and challenges in melanoma immunotherapy |
| title_short | Progress and challenges in melanoma immunotherapy |
| title_sort | progress and challenges in melanoma immunotherapy |
| topic | melanoma immunotherapy cell therapy tumor vaccine immunoresistance |
| url | http://pfxbzlx.gdvdc.com/EN/10.3969/j.issn.1674-8468.2025.07.005 |
| work_keys_str_mv | AT linjing progressandchallengesinmelanomaimmunotherapy AT chenyaying progressandchallengesinmelanomaimmunotherapy AT chenyu progressandchallengesinmelanomaimmunotherapy |